Effects of Different Antagonists in Gonadotropin Releasing Hormone Antagonist Cycles
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0416
- VernacularTitle:不同拮抗剂在促性腺激素释放激素拮抗剂方案中的应用
- Author:
Ting-ting XIA
1
;
Zi-qing WAN
1
;
Lin-lin TAO
1
;
Xiao-qi LIN
1
;
Jian-ping OU
1
Author Information
1. Center for Reproductive Medicine， The Third Affiliated Hospital of Sun Yat-sen University， Guangzhou 510630， China
- Publication Type:Journal Article
- Keywords:
gonadotropin releasing hormone antagonist;
Ganirelix;
Cetrorelix.
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(4):645-652
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo compare the effects of ganirelix1， ganirelix2 and cetrorelix for preventing premature luteinizing hormone （LH） surges and on clinical outcomes in gonadotropin-releasing hormone antagonist （GnRH-ant） cycles. MethodsWe retrospectively analyzed 1434 GnRH-ant cycles of in vitro fertilization/intracytoplasmic sperm injection （IVF/ICSI） at the Reproductive Medical Center of The Third Affiliated Hospital of Sun Yat-sen University from October， 2019 to December， 2020， including 461 cycles with ganirelix 1 treatment （Group 1）， 741 cycles with ganirelix 2 treatment （Group 2） and 232 cycles with cetrorelix treatment （Group 3） . The baseline characteristics of the patients and the clinical outcomes of the three groups were compared. ResultsThere were no significantly differences found in age，body mass index and anti-Müllerian hormone among the three groups. There were no significant differences in number of oocytes， proportion of LH >10 U/L on human chorionic gonadotrophin （hCG） trigger day， incidence of moderate/severe ovarian hyperstimulation syndrome （OHSS）， mature oocytes， clinical pregnancy rate and live birth rate following fresh embryo transfer among the three groups （P > 0.05）. The early pregnancy loss rate of ganirelix 1 group was significantly higher than that of ganirelix 2 group （P < 0.05）. ConclusionThere were similar incidence of premature LH surge in hCG day， moderate/severe OHSS， clinical pregnancy rate and live birth rate in GnRH-ant protocols among the three antagonists. The ganirelix 1 group may have a higher risk of adverse pregnancy outcome following fresh transfer since the high early pregnancy loss rate of it.
